Evidence map›Paper›PMID 41969455›Full record

ArticleTranslational cancer research2026

Jingbin Wu, Jiahao Xia, Yuan Tao, Yiping Weng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jingbin WuDepartment of Orthopedics, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, China.
Jiahao XiaDepartment of Orthopedics, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, China.
Yuan TaoDepartment of Orthopedics, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, China.
Yiping WengDepartment of Orthopedics, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, China.ORCID https://orcid.org/0009-0004-3807-8636

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osteosarcoma (OS) is the most common primary bone malignancy with an incompletely understood pathogenesis. The RNA-binding protein (RBP) insulin-like growth factor 2 messenger RNA (mRNA)-binding protein 3 (IGF2BP3) has been implicated in various cancers, but its role and underlying mechanisms in OS have not been fully elucidated. This study aimed to investigate the molecular function of IGF2BP3 in OS progression and elucidate its mechanisms. Methods: The expression of IGF2BP3 was analyzed in OS tissues and cell lines. Functional assays, including cell proliferation and apoptosis analyses, were performed following Results: IGF2BP3 was significantly overexpressed in OS and associated with poor patient outcomes. Its silencing suppressed OS cell proliferation and induced apoptosis. Mechanistically, Conclusions: IGF2BP3 promotes OS progression by stabilizing

Indexed as

Hippo pathwayInsulin-like growth factor 2 messenger RNA-binding protein 3 (IGF2BP3)osteosarcoma (OS)Ras homolog family member A (RHOA)yes-associated protein (YAP)

Identifiers

PMID41969455
PMCPMC13067189

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.